ab 18 July 2025 Global Research China Healthcare China preclinical CRO expert call takeaways H125: slight price & volume recovery; tipping point may not occur until 2026 On 18 July, we invited a senior executive from a domestic medium-sized preclinical CRO firm to share his views. He noted a slight recovery in China's preclinical CRO industry. Overall order inflow has increased modestly YoY for both volume (up <10%) and price (up 5-10%) YTD, with profits staying low. In his view, pharmaceutical R&D is gener ...